- Home
- DSM vs VNDA Comparison
DSM vs VNDA Comparison
Compare DSM & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DSM | VNDA |
|---|---|---|
| Founded | 1989 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.5M | 398.9M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | DSM | VNDA |
|---|---|---|
| Price | $6.01 | $6.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 161.7K | ★ 1.3M |
| Earning Date | 01-01-0001 | 02-12-2026 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $212,074,000.00 |
| Revenue This Year | N/A | $12.01 |
| Revenue Next Year | N/A | $21.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.12 |
| 52 Week Low | $4.69 | $3.81 |
| 52 Week High | $6.05 | $7.20 |
Technical Indicators
Market Signals| Indicator | DSM | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 54.79 | 66.27 |
| Support Level | $5.93 | $6.15 |
| Resistance Level | $6.02 | $7.20 |
| Average True Range (ATR) | 0.05 | 0.48 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 50.00 | 84.62 |
Price Performance
Historical ComparisonAbout DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.